Sign in
Not yet taking people in United StatesNo phase

Studies how long a leukemia drug stays active in children

Observes how long calaspargase pegol stays active in children with leukemia or lymphoma.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Status
Not yet recruiting
People taking part
20 people, planned
Starts
1 Feb 2027
Expected to end
31 Dec 2028
Type of study
Observational
Treatments tested
  • Non-Interventional Study
Record updated
2 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with acute lymphoblastic leukemia or lymphoma who are being treated by a pediatric hematology team and receive calaspargase as part of their treatment.

Age
Up to 21 years. People older than 21 years cannot join.
Sex
All sexes can join.
Disease stage
Acute lymphoblastic leukemia or lymphoma, treated by the pediatric hematology team.
Earlier treatment
Must be receiving calaspargase as part of treatment for the cancer.

Main reasons for not taking part

  • Age over 21 years
  • Actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab arm
  • Pregnancy

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team
  • Receiving calaspargase as part of treatment for malignancy

Who cannot take part

  • Age > 21 years
  • Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm
  • Pregnancy

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeNot yet recruiting

About the trial

What the trial wants to find out

This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.

The group in the trial

  • Observational

    Patients provide blood samples collected during regularly scheduled appointments and have medical records reviewed throughout the study.

    Treatment: Non-Interventional Study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Plain-language title
Studies how long a leukemia drug stays active in childrenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 April 2026